PF-00477736 mediates checkpoint kinase 1 signaling pathway and potentiates docetaxel-induced efficacy in xenografts.
about
Chemotherapeutic compounds targeting the DNA double-strand break repair pathways: the good, the bad, and the promisingContext-Dependent Cell Cycle Checkpoint Abrogation by a Novel Kinase InhibitorNew insights into checkpoint kinase 1 in the DNA damage response signaling network.Genistein abrogates G2 arrest induced by curcumin in p53 deficient T47D cellsRNAi screen of the protein kinome identifies checkpoint kinase 1 (CHK1) as a therapeutic target in neuroblastomaCombined CDKN1A/TP53 mutation in bladder cancer is a therapeutic target.Development of radiotracers for oncology--the interface with pharmacologyIdentification and evaluation of a potent novel ATR inhibitor, NU6027, in breast and ovarian cancer cell linesConstitutive activation of the DNA damage response pathway as a novel therapeutic target in diffuse large B-cell lymphomaIn vitro and in vivo single-agent efficacy of checkpoint kinase inhibition in acute lymphoblastic leukemiaIdentification of novel, in vivo active Chk1 inhibitors utilizing structure guided drug design.Neuroblastoma and MYCNMonitoring metabolic responses to chemotherapy in single cells and tumors using nanostructure-initiator mass spectrometry (NIMS) imaging.Targeting CDC25C, PLK1 and CHEK1 to overcome Docetaxel resistance induced by loss of LZTS1 in prostate cancer.Harnessing the complexity of DNA-damage response pathways to improve cancer treatment outcomes.Cytosine Deaminase APOBEC3A Sensitizes Leukemia Cells to Inhibition of the DNA Replication Checkpoint.Targeting the ATR-CHK1 Axis in Cancer TherapyCHK1 overexpression in T-cell acute lymphoblastic leukemia is essential for proliferation and survival by preventing excessive replication stress.Defective cell cycle checkpoints as targets for anti-cancer therapies.ATR/CHK1 inhibitors and cancer therapy.
P2860
Q26863501-2D54EDB5-6FA3-48EB-8169-7DA9DD3CC250Q27665373-DE522E16-8716-4272-B3AB-FBD0D8B5040AQ34129155-C8600287-3735-4DA1-A881-E2BD33DCAF68Q34564108-C9E1DA44-3D1F-4B59-A7F2-DE944E0E897FQ34602599-A251E841-33E0-4104-AB34-EAF0EEE0041EQ34978486-E933E1F4-5AC8-41F3-82B0-B7B961D4E445Q35195500-B5CDC758-FD30-48B7-A35C-631845647821Q35212640-BBBF30A6-125E-4E0D-88FE-F765A201CC38Q35740025-4FEFB524-C81D-44AC-9D9C-B411AF6DEA55Q36255484-AEB3705B-88C8-47FA-9B0D-36145A0D1B05Q36546469-96A05A54-2232-474C-9594-919D36C2D354Q37201479-39E50782-3F35-46AD-A6AF-71CDE04E2C2FQ37326605-FEF5BD1E-B935-4E3E-8F96-6BC61A733DA5Q37718444-22B530F4-E975-4C36-8E8F-8B52DAF1936DQ37785490-8592794F-2370-43EA-90C9-921CFF71B6A3Q38698806-0FAECC62-C9B6-4685-9C9E-A8395BDD6095Q38817102-DD2C5743-156C-4327-B213-7614F079A2A4Q38965035-AB9775AA-179E-4879-B793-E4E80FCB281AQ40794273-478F7A5E-73F7-4A9E-AABC-1CEA5512D10DQ47622968-F3E08259-3DDA-4FD6-B2F3-BE4CAF982A14
P2860
PF-00477736 mediates checkpoint kinase 1 signaling pathway and potentiates docetaxel-induced efficacy in xenografts.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
2009年论文
@zh
2009年论文
@zh-cn
name
PF-00477736 mediates checkpoin ...... nduced efficacy in xenografts.
@en
type
label
PF-00477736 mediates checkpoin ...... nduced efficacy in xenografts.
@en
prefLabel
PF-00477736 mediates checkpoin ...... nduced efficacy in xenografts.
@en
P2093
P1476
PF-00477736 mediates checkpoin ...... nduced efficacy in xenografts.
@en
P2093
Anthony Wong
Cathy Zhang
Cory L Painter
Dana Buckman
Enhong Chen
Guizhen Sun
James G Christensen
Jill Hallin
Kenna Anderes
Kenneth Zasadny
P304
P356
10.1158/1078-0432.CCR-08-3272
P407
P577
2009-07-07T00:00:00Z